<DOC>
	<DOCNO>NCT00911898</DOCNO>
	<brief_summary>This study open-label Phase 1 trial MM-111 .</brief_summary>
	<brief_title>A Study MM-111 Patients With Advanced , Refractory Her2 Amplified , Heregulin Positive Cancers</brief_title>
	<detailed_description>Phase 1 : Patients solid tumor type may enrol evaluate safety tolerability MM-111 .</detailed_description>
	<criteria>Patients must histologically cytologically confirm advanced cancer : HER2 amplify ( IHC 2+ great ) base archived tumor evaluation Heregulin positive base study require fresh biopsy sample perform screen confirmed central laboratory Patients must block archive formalinfixed , paraffinembedded tumor tissue available section immunohistochemical stain Patient 's cancer must recur progress follow standard therapy , respond standard therapy , standard therapy exists . Patients must &gt; = 18 year age Patients legal representative must able understand sign inform consent Patients may measurable nonmeasurable tumor ( ) Patients ECOG Performance Score ( PS ) 0 1 Patients must adequate bone marrow reserve evidence : Absolute neutrophil count ( ANC ) &gt; = 1,500/uL Platelet count &gt; = 100,000/uL Hemoglobin &gt; = 9 g/dL Patients must tumor tissue amenable biopsy Patients must willing undergo biopsy prior treatment MM111 Patients potentially curative antineoplastic therapy available Patients pregnant lactate Patients active infection unexplained fever great 38.5 C screen visit first schedule day dose . ( At discretion investigator , patient tumor fever may enrol ) Patients untreated and/or symptomatic primary metastatic CNS malignancy ( patient CNS metastases undergone surgery radiotherapy , whose disease stable , stable dose corticosteroid least 2 week prior first schedule day dose eligible trial Patients know hypersensitivity component MM111 hypersensitivity reaction fully human monoclonal antibody ( patient history hypersensitivity trastuzumab , humanize antibody , exclude ) Patients know HIV , hepatitis B C ( patient previously treat C undetectable viral load , consider eligible trial )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Her2 amplify solid tumor</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Her3/ErbB3</keyword>
	<keyword>Bispecific Antibody</keyword>
</DOC>